Overview

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
A single-dose pilot study of an investigational capsule formulation of 2 mg/.05 mg Buprenorphine/Naloxone. NIDA Contract No. HHSN271200577414C
Details
Lead Sponsor:
NanoSHIFT LLC
Nanotherapeutics, Inc.
Treatments:
Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone